congenital fibrosarcoma | ClinicalTrials HQ

View definition

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors	Carcinoma, Medullary, Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Thyroid Cancer, Papillary, adenocarcinoma, breast disorder, breast neoplasm, bronchial disorder, bronchial neoplasm, bronchogenic carcinoma, carcinoma, central nervous system cancer, colonic disorder, colonic neoplasm, colorectal neoplasm, congenital fibrosarcoma, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, infantile myofibromatosis, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, medullary thyroid gland carcinoma, neoplasm, nervous system disorder, neuroendocrine carcinoma, neuroendocrine neoplasm, non-small cell lung carcinoma, papillary adenocarcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder, thyroid gland disorder, thyroid tumor	Active, not recruiting	Phase 1 / Phase 2	2026-01-06		NCT03899792
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia	Neoplasms by Site, central nervous system cancer, congenital fibrosarcoma, neoplasm, nervous system disorder	Active, not recruiting	Phase 2	2025-12-02		NCT03834961